SHANGHAI, CHINA---- Recently, QureBio (Shanghai) Co., Ltd. (hereinafter referred to as QureBio), which is invested and incubated by Viva BioInnovator and focused on the R&D of innovative macromolecular biopharmaceuticals, announced that the Center for Drug Evaluation, NMPA, has accepted the clinical trial application of its recombinant anti-Claudin 18.2 and PD-L1 humanized bispecific antibody for injection (code: Q-1802) according to "Category 1 of Therapeutic Biological Novel Products".

Official data shows that Q-1802 is the first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.